KOSDAQMachinery348340

Neuromeka

₩14,000▲ 6.87%2026-11-18 close
Market Cap
₩327.7B
Turnover
₩2.5B
Volume
180K
Shares out.
23.4M
PER
—
PBR
2.8×
EPS
-₩2,421
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Decline and Losses Test Neuromeka's Humanoid Pivot

Neuromeka's 2025 sales fell 25.0% from the prior year while operating losses continued, leaving the expansion of its cobot automation solutions and the certification push for its EIR humanoid as the key tests for an earnings recovery.

  1. 1

    Sales in 2025 were KRW 19 billion, down 25.0% from the prior year, and the operating loss was KRW 14.9 billion.

  2. 2

    Sales in the third quarter of 2026 were KRW 2.78 billion, down for a third straight quarter after the fourth-quarter 2025 peak, and the operating loss widened to KRW 7 billion.

  3. 3

    The company said on June 15, 2026 that it supplies turnkey cobot automation to POSCO, HD Hyundai Samho Heavy Industries, DN Solutions and Hankook Kolmar, and is negotiating supply with new customers.

  4. 4

    The company said the EIR humanoid is preparing for cobot certification, which would allow deployment in small and mid-sized factories without safety fencing.

  5. 5

    At year-end 2025, total liabilities were KRW 77.5 billion against total equity of KRW 13.9 billion, a debt-to-equity ratio of 557.6%.

02

Business structure

Neuromeka develops its own robot bodies, controllers and software, centered on collaborative robots. Its main lines are the Indy, OPTi and Nuri cobots, and it is separately developing the EIR humanoid platform.

The Pohang production base has equipment capable of building up to 1,000 cobots a year, according to a February 2026 report. Indy and OPTi are built on the company's own hardware, while Nuri uses hardware sourced from China's ROKAE.

The 3, 5, 7 and 12 kg payload models are made in-house, while 30 kg and 50 kg heavy-payload robots use externally sourced hardware for cost reasons. The company says internalizing core parts such as motors and links helps it keep quality consistent.

Vision Pro and Vision X models make up about half of total production volume, according to an on-site official. The company says it is shifting its focus from standalone robot sales toward turnkey system integration covering process analysis, design, installation and maintenance.

Disclosed key customers include POSCO for steel-line processing, inspection and logistics automation, HD Hyundai Samho Heavy Industries for welding-specialized cobots, DN Solutions and DN Automotive for machine tending, and Hankook Kolmar for cosmetics testing automation.

It competes with cobot-focused listed peers such as Doosan Robotics and Rainbow Robotics, and it stresses parts internalization and domain-specific integration as its differentiators.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.5B-₩3.2B−70.7%
2025Q4₩7.9B-₩3.5B−44.6%
2026Q1₩3B-₩4.3B−144.2%
2026Q2₩2.8B-₩5.3B−186.6%
2026Q3₩2.8B-₩7B−252.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.8B-₩7.8B-₩8.2B−79.9%−20.6%10.3%
2023₩13.7B-₩14.8B-₩17.7B−107.9%−73.4%297.9%
2024₩25.3B-₩19B-₩16.7B−75.2%−153.4%776.1%
2025₩19B-₩14.9B-₩22B−78.4%−158.3%557.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, Neuromeka's sales rose from KRW 9.75 billion in 2022 to KRW 13.7 billion in 2023 (up 40.9% year on year) and KRW 25.3 billion in 2024 (up 83.9%), making 2024 the largest year in the 2022 to 2025 span. Sales fell 25.0% to KRW 19 billion in 2025.

The operating loss was KRW 7.8 billion in 2022, KRW 14.8 billion in 2023, KRW 19 billion in 2024 and KRW 14.9 billion in 2025, so the company has posted operating losses for four consecutive years from 2022 to 2025.

Even in 2024, the year of highest sales, the operating loss was the largest in the period at KRW 19 billion, and the operating margin was -75.2%. The operating margin was lowest in 2023 at -107.9% and was -78.4% in 2025.

Net loss attributable to controlling shareholders grew from KRW 8.2 billion in 2022 to KRW 17.7 billion in 2023 and KRW 16.7 billion in 2024, and reached KRW 22 billion in 2025, the largest of the four years.

Net loss including non-controlling interests was KRW 16.8 billion in 2024, a different figure from the controlling-shareholder loss of KRW 16.7 billion, so the two should be read separately.

Operating cash flow was -KRW 8 billion in 2022, -KRW 12.4 billion in 2023, -KRW 21.9 billion in 2024 and -KRW 11.4 billion in 2025, an outflow in every year.

The debt-to-equity ratio rose from 10.3% in 2022 to 297.9% in 2023 and 776.1% in 2024 before easing to 557.6% in 2025, when total equity was KRW 13.9 billion and total liabilities were KRW 77.5 billion.

On a quarterly basis, sales peaked at KRW 7.87 billion in the fourth quarter of 2025 (up 75.9% from the prior quarter), then fell to KRW 2.99 billion, KRW 2.82 billion and KRW 2.78 billion in the first three quarters of 2026, and third-quarter 2026 sales were down 37.9% year on year.

Over the same span the operating loss went from KRW 3.16 billion in the third quarter of 2025 to KRW 3.51 billion, KRW 4.31 billion, KRW 5.27 billion and KRW 7 billion in the third quarter of 2026, five consecutive loss quarters with a widening gap.

The controlling-shareholder net loss in the first quarter of 2026 was KRW 25.6 billion, far above that quarter's operating loss of KRW 4.31 billion, and how much non-operating items explain that gap should be checked against the detailed filings.

The combined controlling-shareholder net loss for the last four quarters (fourth quarter 2025 to third quarter 2026) was KRW 43.1 billion.

05

Industry analysis

The cobot market Neuromeka operates in covers industrial robots that work alongside people, and in Korea it competes with listed names such as Doosan Robotics and Rainbow Robotics as well as overseas vendors.

Samsung Electronics became the largest shareholder of Rainbow Robotics in early 2025, which put the humanoid technology race in sharper focus. Neuromeka has chosen to produce cobot hardware in-house to manage cost and quality.

On the demand side, the company says its automation is reaching more manufacturing sites, including steel, shipbuilding, automotive and cosmetics. The company argues that competition in automation is shifting from standalone robots toward solutions built on understanding the actual production site.

Reporting in April 2026 said its work with POSCO has expanded automation scope from the cell level to the line level. At the same time, Nuri's reliance on hardware from a Chinese supplier is a supply-chain point that needs monitoring.

Partner companies such as POSCO Future M and Ecopro Group have production sites clustered near the Pohang base, which reports cite as a geographic advantage for joint demonstrations.

Relative to peers, Neuromeka emphasizes in-house cobot parts and experience in industry-specific integration, while its 2025 sales were KRW 19 billion on a disclosed basis.

06

Outlook

In an interview at the start of 2026, Neuromeka said it planned to launch the EIR humanoid in the first half of 2026 and also to release 30 kg and 50 kg heavy-payload cobots.

In the same interview, the company described a plan to replace the Japanese Harmonic Drive gear reducers used in the fourth through sixth joints of its OPTi cobot with in-house products, which it said would make it the first domestic cobot model with both reducer and motor sourced in Korea.

The company also said a humanoid needs cobot certification to be meaningful on industrial sites. At SIMTOS 2026 in April 2026, the EIR was unveiled and introduced as the first domestic humanoid built on a dual-arm cobot, with certification being prepared.

According to the company, once certified it could be deployed at small and mid-sized factories without safety fencing. In June 2026 the company said it was negotiating supply with prospective customers in steel, shipbuilding and automotive.

In July 2026 it announced that it had been selected as the supply partner for a gear-machining automation project at an automotive parts maker, where it supplies second-generation cobots.

Reports say the company is building a new headquarters and a second plant near the Pohang site, which could expand production capacity. Points to confirm next are the EIR's certification and shipment timing, whether heavy-payload cobots are launched, and the size and revenue timing of new supply contracts.

The 2026 annual report, the next periodic filing, will show how sales and the operating loss moved after the fourth quarter of 2025.

07

Valuation

PER
—
PBR
2.8×
ROE
-72.9%
EPS
-₩2,421
BPS
₩5,336
Dividend per share
₩0

Neuromeka has reported net losses attributable to controlling shareholders for the last four quarters, so a price-to-earnings multiple cannot be calculated on a trailing four-quarter basis. Valuation interpretation therefore rests more on asset and capital-structure measures than on earnings.

The price-to-book ratio sits at a large premium to net asset value, which reads as a question of how much of the humanoid and cobot business expectation the market is already pricing in versus current results.

Total equity at year-end 2025 was KRW 13.9 billion against total liabilities of KRW 77.5 billion, so the debt burden relative to equity is large and should be considered alongside any net-asset-based metric. Dividends are effectively absent while losses continue.

Historical trading-band comparisons are limited because operating losses have persisted since 2022, leaving no stable earnings base to measure against.

Whether the company raises additional funds will drive changes in total equity, so future capital-raising or borrowing disclosures are a key variable for reading the net-asset metrics.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

In-house parts control cost and quality

Neuromeka says it makes core parts such as motors and links in-house to reduce outsourcing and keep quality consistent. Its 3 to 12 kg models are self-manufactured, while 30 kg and 50 kg units rely on externally sourced hardware to balance cost.

A planned swap of Japanese reducers in the OPTi's fourth through sixth joints would, according to the company, make it the first domestic cobot with both reducer and motor sourced in Korea.

Turnkey automation widens the customer base

Working with POSCO, HD Hyundai Samho Heavy Industries, DN Solutions and Hankook Kolmar, the company is extending its automation into steel, shipbuilding, automotive and cosmetics. It plans to standardize and modularize industry-specific solutions to shorten development time and improve cost competitiveness.

Negotiations with prospective customers are under way in each sector, so new orders converting into revenue could support a recovery in the top line.

EIR humanoid and the certification strategy

The EIR was introduced as the first domestic humanoid built on a dual-arm cobot and is preparing for cobot certification. The company says certification would allow deployment at small and mid-sized factories without safety fencing.

It also outlined a strategy of using physical AI-based automation to lower integration costs compared with its existing system-integration model and to improve process flexibility.

09

Bear factors

Three straight quarters of sales decline, widening losses

After peaking at KRW 7.87 billion in the fourth quarter of 2025, sales declined in each quarter through the third quarter of 2026, with third-quarter sales down 37.9% from a year earlier. Over the same period the operating loss widened to KRW 7 billion in the third quarter of 2026.

The 2025 sales of KRW 19 billion were 25.0% below 2024, and the recovery has not yet appeared in reported results.

Debt against a thin equity base and ongoing cash outflows

Total liabilities of KRW 77.5 billion at year-end 2025 far exceeded total equity of KRW 13.9 billion, putting the debt-to-equity ratio at 557.6%. Operating cash flow was negative in every year from 2022 to 2025, with KRW 21.9 billion leaving in 2024.

If losses continue, additional fundraising may be needed, so the size of financial headroom is the central question.

Uncertainty over humanoid certification and launch timing

In an early 2026 interview, the company said a humanoid with a mobile base had no certification standard and therefore could not yet be certified. It chose to pursue cobot certification with redundant sensors instead.

Whether the first-half 2026 launch plan was carried out should be tracked through company filings and press reports.

10

Risk factors

Financing and funding

Operating losses have continued every year since 2022 and widened to KRW 7 billion in the third quarter of 2026. Operating cash flow has also been negative every year, so how long KRW 13.9 billion of equity can absorb losses is the central question. Any further fundraising would also raise the possibility of dilution for existing shareholders.

Conversion of orders into revenue

The company says negotiations with prospective steel, shipbuilding and automotive customers are still ongoing. How much of this pipeline will turn into actual revenue is hard to gauge before the relevant filings. If revenue is recognized on a project basis, quarter-to-quarter swings could be large.

Certification and supply chain

Because the EIR is still preparing for cobot certification, any delay would push back its launch schedule. On cost, the 30 kg and 50 kg models depend on externally sourced hardware and Nuri relies on a Chinese supplier, so supply-chain shifts could affect margins. How far in-house parts production is maintained is also a point to monitor.

11

What to watch next

  1. After December 2026 (date not set)

    Whether the EIR completes cobot certification and when shipments begin. The company says certification is needed before deployment without safety fencing, so it would be the first signal of a change in revenue mix.

  2. Around January to February 2027 (typical timing)

    The fourth-quarter 2026 results announcement. Checks whether sales rebound from the third-quarter 2026 level of KRW 2.78 billion and whether the five-quarter run of widening operating losses stops.

  3. By March 31, 2027

    Filing of the 2026 annual report. This is where annual sales, operating loss, operating cash flow and the debt-to-equity ratio are confirmed against the DART periodic filing.

  4. After late 2026 (completion date not set)

    The completion timing of the new Pohang headquarters and second plant, and whether capacity expansion translates into higher shipments from the site's current capacity of up to 1,000 cobots a year.

12

Overall view

Neuromeka posted operating losses in each year from 2022 to 2025, and 2025 sales fell 25.0% to KRW 19 billion. Quarterly trends in 2026 show sales declining for three straight quarters and operating losses widening over five consecutive loss quarters.

The controlling-shareholder net loss was KRW 22 billion in 2025, the largest of the four years, and it was KRW 25.6 billion in the first quarter of 2026 before narrowing to KRW 4.5 billion in the second quarter and widening to KRW 7.2 billion in the third quarter.

On the financial side, total liabilities of KRW 77.5 billion against equity of KRW 13.9 billion at year-end 2025 left a debt-to-equity ratio of 557.6%, and operating cash flow was negative every year.

On the business side, the strengths cited are in-house parts, turnkey automation with large customers such as POSCO and HD Hyundai Samho Heavy Industries, and the certification effort for the EIR humanoid.

When the announced supply negotiations and expanded Pohang capacity show up in reported results is the next point to confirm. For valuation, no earnings-based multiple can be calculated, so the net-asset metrics and any fundraising are central to interpretation.

The next checkpoints are the direction of sales and operating loss in the 2026 annual report and the certification progress of the EIR.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. irobotnews.com
  2. zdnet.co.kr
  3. economic22.com
  4. news.nate.com
  5. fajournal.com
  6. newspim.com
  7. daily.hankooki.com
  8. etnews.com
  9. m.news.nate.com
  10. finance-scope.com
  11. markets.hankyung.com
  12. hongcenter.com
  13. littlebproject.com
  14. littlebproject.com
  15. dailyinvest.kr
  16. antwinner.com
  17. littlebproject.com
  18. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis